Premium
A.S.P.E.N. Position Paper
Author(s) -
Vanek Vincent W.,
Borum Peggy,
Buchman Alan,
Fessler Theresa A.,
Howard Lyn,
Jeejeebhoy Khursheed,
Kochevar Marty,
Shenkin Alan,
Valentine Christina J.
Publication year - 2012
Publication title -
nutrition in clinical practice
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.725
H-Index - 71
eISSN - 1941-2452
pISSN - 0884-5336
DOI - 10.1177/0884533612446706
Subject(s) - medicine , parenteral nutrition , ergocalciferol , vitamin d and neurology , multivitamin , intensive care medicine , vitamin , pediatrics , cholecalciferol
The parenteral multivitamin preparations that are commercially available in the United States (U.S.) meet the requirements for most patients who receive parenteral nutrition (PN). However, a separate parenteral vitamin D preparation (cholecalciferol or ergocalciferol) should be made available for treatment of patients with vitamin D deficiency unresponsive to oral vitamin D supplementation. Carnitine is commercially available and should be routinely added to neonatal PN formulations. Choline should also be routinely added to adult and pediatric PN formulations; however, a commercially available parenteral product needs to be developed. The parenteral multi–trace element (TE) preparations that are commercially available in the U.S. require significant modifications. Single‐entity trace element products can be used to meet individual patient needs when the multiple‐element products are inappropriate (see Summary/A.S.P.E.N. Recommendations section for details of these proposed modifications).